---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000837488.md"
description: "$Eli Lilly(LLY.US) +5% premarket after the drugmaker posted 2Q sales ahead of expectations on the strength of its obesity drugs and raised FY’26 revenue full-year forecast above expectations.  Foundayo revs (weight loss pill) launched in June beat expectations.FY’2026 guidance: - Sees Revs $85.0B to $87.0B, saw $82.0B to $85.0B, vs $85.31B est. - Sees Adj EPS $35.50 to $36.50, saw $35.50 to $37 vs $33.56 est.2Q results:- Adj EPS $8.38 +32% Y/Y vs. $6.37 est- Revs $22.97 billion, +48% y/y, vs $20.59 estimate - Mounjaro revenue $9.94B vs $8.83B est- Zepbound revenue $4.93B vs $4.64B - Foundayo revenue $98M vs $92M est- Trulicity revenue $1.22B vs $869M est- Verzenio rev. $1.47B, -1% y/y, vs $1.5B est- Taltz rev. $856M vs $854.7M est- R&D expenses $3.82B vs $4.05B est"
datetime: "2026-08-05T12:06:48.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000837488.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000837488.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000837488.md)
author: "[Gary Black Tracker](https://longbridge.com/en/profiles/17077344.md)"
generator: "portal-rs"
---

# $Eli Lilly(LLY.US) +5% premarket after the drugmak…


### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**